Danish drug maker Novo Nordisk (NVO) announced a stock split in the ratio of 5:1 on its ADRs recently. The effective date of the split is Jan 9, 2014 and the record date is Jan 3, 2014.
From the...(read more
[at Motley Fool] - Novo Nordisk (NVO) and Eli Lilly (LLY) are giants when it comes to treating diabetes, but is one a better buy than the other? Read more on this. Eli Lilly and Company (LLY), valued at $53.32B, started the session at $49.61. Today’s price range has [...]
Novo Nordisk (NVO) recently announced positive phase III data on its hemophilia B candidate, N9-GP, from the paradigm 2 study.
Paradigm 2 evaluated N9-GP, a long-acting FIX...(read more